Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim R Cressey

Showing results (61-70 of 166) with videos related to

Pageof 17
Sort By:
BMC Infectious Diseases|February 24, 2026
SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistanceCarlos Grasa, Nicolas Salvadori, Alessandra Nardone, et al.
Journal of the International AIDS Society|June 19, 2026
Acceptability of a Dolutegravir Oral Dispersible Film in Term Neonates Born to Mothers Living With HIVLario Viljoen, Charlene Purdy, Verah Luke, et al.
The Pediatric Infectious Disease Journal|September 12, 2018
Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral ProphylaxisSuvaporn Anugulruengkitt, Tim R Cressey, Piyarat Suntarattiwong, et al.
Plos One|February 22, 2024
A pilot program of HIV pre-exposure prophylaxis in Thai youthSupattra Rungmaitree, Peerawong Werarak, Wadchara Pumpradit, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartumTim R Cressey, Alice Stek, Edmund Capparelli, et al.
Antiviral Therapy|October 11, 2017
Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescentsWatsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Naruporn Kasipong, et al.
The Pediatric Infectious Disease Journal|May 18, 2016
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young AdultsMarc Foca, Ram Yogev, Andrew Wiznia, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patientsNaïm Bouazza, Tim R Cressey, Frantz Foissac, et al.
Viruses|August 28, 2021
Lack of Association between Adverse Pregnancy Outcomes and Zika Antibodies among Pregnant Women in Thailand between 1997 and 2015Nicole Ngo-Giang-Huong, Charline Leroi, Dahlene Fusco, et al.
The Pediatric Infectious Disease Journal|September 2, 2016
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young AdultsTim R Cressey, Rohan Hazra, Andrew Wiznia, et al.
Pageof 17

Showing results (61-70 of 166) with videos related to

Sort By:
Pageof 17
BMC Infectious Diseases|February 24, 2026
SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistanceCarlos Grasa, Nicolas Salvadori, Alessandra Nardone, et al.
Journal of the International AIDS Society|June 19, 2026
Acceptability of a Dolutegravir Oral Dispersible Film in Term Neonates Born to Mothers Living With HIVLario Viljoen, Charlene Purdy, Verah Luke, et al.
The Pediatric Infectious Disease Journal|September 12, 2018
Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral ProphylaxisSuvaporn Anugulruengkitt, Tim R Cressey, Piyarat Suntarattiwong, et al.
Plos One|February 22, 2024
A pilot program of HIV pre-exposure prophylaxis in Thai youthSupattra Rungmaitree, Peerawong Werarak, Wadchara Pumpradit, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartumTim R Cressey, Alice Stek, Edmund Capparelli, et al.
Antiviral Therapy|October 11, 2017
Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescentsWatsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Naruporn Kasipong, et al.
The Pediatric Infectious Disease Journal|May 18, 2016
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young AdultsMarc Foca, Ram Yogev, Andrew Wiznia, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patientsNaïm Bouazza, Tim R Cressey, Frantz Foissac, et al.
Viruses|August 28, 2021
Lack of Association between Adverse Pregnancy Outcomes and Zika Antibodies among Pregnant Women in Thailand between 1997 and 2015Nicole Ngo-Giang-Huong, Charline Leroi, Dahlene Fusco, et al.
The Pediatric Infectious Disease Journal|September 2, 2016
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young AdultsTim R Cressey, Rohan Hazra, Andrew Wiznia, et al.
Pageof 17